In conclusion, because of consistency and robustness, specific phospholipids identified in our study fit the criteria for a phase 1/2 markers [46], especially if they can be combined with PSA and DRE screening for the diagnosis of PCa. This evidence concerns the gene KLK3 and posterior cortical atrophy.